



Meningococcal polysaccharide vaccine group W-135

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

IDENTIFICATION

Name	Meningococcal polysaccharide vaccine group W-135
Accession Number	DB13887 (DB10074)
Type	Biotech
Groups	Approved, Experimental, Investigational
Biologic Classification	Vaccines Other vaccines

Description Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup W-135. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

Synonyms Meningococcal polysaccharide antigen group W-135
neisseria meningitidis group W-135 capsular polysaccharide antigen
Neisseria meningitidis group W-135 polysaccharide antigen, A


Mixture Products Show entries

NAME	INGREDIENTS	DOSAGE	ROUTE	LABELLER	MARKETING START	MARKETING END	
Menomune - A/c/y/w-135 Combined	Meningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL)	Kit		Sanofi Pasteur Limited	1981-11-23	Not applicable	

Drugs



135	vaccine group W-135 (2.5 mg) + Meningococcal polysaccharide vaccine group A (2.5 mg) + Meningococcal polysaccharide vaccine group C (2.5 mg) + Meningococcal polysaccharide vaccine group Y (2.5 mg)								
Menomune-A/c/y/w-135	Meningococcal polysaccharide vaccine group W-135 (500 mcg) + Meningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg) + Meningococcal polysaccharide vaccine group Y (500 mcg)	Powder, for solution	Subcutaneous	Sanofi Pasteur Limited	1983-12-31	2017-04-05			
Menomune-A/c/y/w-135	Meningococcal polysaccharide vaccine group W-135 (50 mcg) + Meningococcal polysaccharide vaccine group A (50 mcg) + Meningococcal polysaccharide vaccine group C (50 mcg) + Meningococcal polysaccharide vaccine group Y (50 mcg)	Kit; Powder, for solution	Subcutaneous	Sanofi Pasteur Limited	1993-10-29	2017-04-05			

	vaccine group W-135 (5 mcg/0.5mL) + Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group Y (5 mcg/0.5mL)	Solution							<input type="button" value="<<"/>
Nimenrix	Meningococcal polysaccharide vaccine group W-135 (5 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) , (44 mcg) + Meningococcal polysaccharide vaccine group A (5 mcg) + Meningococcal polysaccharide vaccine group C (5 mcg) + Meningococcal polysaccharide vaccine group Y (5 mcg)	Kit; Powder, for solution	Intramuscular	Pfizer	2013-08-22	Not applicable			

Showing 1 to 6 of 6 entries < 1 >

Categories [Actively Acquired Immunity](#) [Inactivated Meningococcal Vaccine](#)

UNII [9F8QQ6EER1](#)

CAS number Not Available

PHARMACOLOGY

Indication Not Available

Associated [Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup W-135](#)

Pharmacodynamics Not Available

Mechanism of action Not Available



Absorption Not Available

Volume of distribution Not Available

Protein binding Not Available

Metabolism Not Available

Route of elimination Not Available

Half life Not Available

Clearance Not Available

Toxicity Not Available

Affected organisms Not Available

Pathways Not Available

Pharmacogenomic Effects/ADRs

INTERACTIONS

Drug Interactions Not Available

Food Interactions Not Available

REFERENCES

General References Not Available

External Links PubChem Substance [347911456](#)

FDA label [Download](#) (83.9 KB)

CLINICAL TRIALS

Clinical Trials

Show entries

PHASE	STATUS	PURPOSE	CONDITIONS	COUNT
1	Not Yet Recruiting	Prevention	Infections, Respiratory Syncytial Virus	1
1, 2	Recruiting	Prevention	Respiratory Syncytial Virus (RSV)	1
2	Completed	Prevention	Healthy Volunteers / Meningococcal Infections	1

			Meningitis	
2	Completed	Prevention	Meningococcal Disease / Meningococcal Infections	1
2	Completed	Prevention	Meningococcal Infections	1
2	Recruiting	Prevention	Meningococcal Meningitis	1
3	Completed	Prevention	Bacterial Infections / Neisseria Meningitidis / Virus Diseases	1
3	Completed	Prevention	Invasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections	1
3	Completed	Prevention	Meningitis / Meningococcal Meningitis	1

Showing 1 to 10 of 16 entries ⏪ 1 2 ⏩



PHARMACOECONOMICS

Manufacturers Not Available

Packagers Not Available

Dosage forms Show entries

FORM	ROUTE	STRENGTH
Kit		
Kit; powder, for solution	Subcutaneous	
Powder, for solution	Subcutaneous	
Powder, for solution; solution	Intramuscular	
Kit; powder, for solution	Intramuscular	

Showing 1 to 5 of 5 entries ⏪ 1 ⏩

Prices Not Available

Patents Not Available

PROPERTIES

State Not Available

Experimental Properties Not Available

TAXONOMY

Classification Not classified

Drug created on September 08, 2017 14:22 / Updated on November 02, 2018 07:47

- About
- [About DrugBank](#)
- [DrugBank Blog](#)
- [Wishart Research Group](#)
- [Terms of Use](#)
- [Privacy Policy](#)

- Support
- [FAQ](#)
- [Help](#)
- [Email Support](#)




Commercial Products
[API Pricing](#)

This project is supported by the **Canadian Institutes of Health Research** (award #111062), **Alberta Innovates - Health Solutions** and by **The Metabolomics Innovation Centre (TMIC)**, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome British Columbia**, and **Genome Canada**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the

Drugs

